Abstract:AIM To evaluate the safety of lamivudine (LAM) treatment for chronic hepatitis B in early pregnancy. METHODS A total of 92 pregnant women who received LAM treatment either before pregnancy or in early pregnancy were enrolled in this study. All of the pregnant women volunteered to take lamivudine during pregnancy and were not co-infected with hepatitis C virus, human immunodeﬁciency virus, cytomegalovirus, or other viruses. All infants received passive-active immunoprophylaxis with 200 IU hepatitis B immunoglobulin and three doses of 10 μg hepatitis B vaccines (0-1-6 mo) according to the guidelines for the prevention and treatment of chronic hepatitis B. Adverse events were observed throughout the entire pregnancy and perinatal period, and the effectiveness of lamivudine treatment for blocking mother-to-infant transmission of hepatitis B virus (HBV) was evaluated. All adverse events in mothers and infants during pregnancy and the perinatal period and the HBV mother-to-infant transmission blocking rate were compared with the literature. RESULTS Among the 92 pregnant women, spontaneous abortions occurred in 11 cases, while 3 mothers had a second pregnancy after the initial abortion; 72 mothers delivered 73 live infants, of whom 68 infants were followed up for no less than 6 mo, and 12 mothers were still pregnant. During pregnancy, the main maternal adverse events were vaginitis (12/72, 16.7%), spontaneous abortion (11/95, 11.6%), and gestational diabetes (6/72, 8.3%); only one case had 1-2 degree elevation of the creatine kinase level (195 U/L). During the perinatal period, the main maternal adverse events were premature rupture of the membranes (8/72, 11.1%), preterm delivery (5/72, 6.9%), and meconium staining of the amniotic fluid (4/72, 5.6%). In addition, 2 infants were found to have congenital abnormalities; 1 had a scalp hemangioma that did not change in size until 7 mo, and the other had early cerebral palsy, but with rehabilitation training, the infant's motor functions became totally normal at 2 years of age. The incidence of adverse events among the mothers or abnormalities in the infants was not higher than that of normal mothers or HBV-infected mothers who did not receive lamivudine treatment. In only 2 cases, mother-to-infant transmission blocking failed; the blocking rate was 97.1% (66/68), which was higher than has been previously reported. CONCLUSION Lamivudine treatment is safe for chronic HBV-infected pregnant mothers and their fetuses with a gestational age of less than 12 wk or throughout the entire pregnancy.

Efficacy and Safety of Lamivudine Treatment for Chronic Hepatitis B in Pregnancy

Safety of Lamivudine Treatment for Chronic Hepatitis B in Early Pregnancy

Safety of Anti-hepatitis B Virus Therapy During Pregnancy and Lactation

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis

Safety and Efficacy of Lamivudine or Telbivudine Started in Early Pregnancy for Mothers with Active Chronic Hepatitis B

Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations

Prospective Cohort Study on the Efficacy and Safety of Telbivudine Used Throughout Pregnancy in Blocking Mother-to-child Transmission of Hepatitis B Virus.

Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus

Safety and Efficacy of Telbivudine in Late Pregnancy to Prevent Mother‐to‐child Transmission of Hepatitis B Virus: A Multicenter Prospective Cohort Study

Safety of Telbivudine Treatment for Chronic Hepatitis B for the Entire Pregnancy

Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review

Telbivudine Can Safely Reduce Mother-to-child Transmission in Chronic Hepatitis B Women after 12 Weeks of Gestation

Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus

Evaluation of the Efficacy and Safety of Telbivudin in Preventing Mother-to-infant HBV Transmission

A Study on the Clinical and Pathological Efficacy of Lamivudine in the Treatment of Chronic Hepatitis B

The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B

Successful Treatment of Infantile Hepatitis B with Lamivudine: A Case Report.

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Issues Meriting Further Study in Preventing Mother-to-Infant Transmission of Hepatitis B by Antiviral Therapy During Pregnancy